ImmunityBio shares are trading higher after the company announced successful completion of manufacturing engineering programs, NK2022 and NK2023, for its M-ceNK memory cytokine-enhanced natural killer cell therapy platform. Also, the Phase I program combining M-ceNK with ANKTIVA has enrolled 74 subjects.